Where Does Fulgent Genetics Go From Here?
Fulgent Genetics (NASDAQ: FLGT) capped off 2020 with a mammoth fourth quarter. Revenue was up 3,400% thanks to the company's move into COVID-19 testing. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss Fulgent's guidance for 2021, the challenges the genetic testing company faces, and what investors should be focused on in the months and years to come.
Source Fool.com
